Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference.
(Reporting by Yew Lun Tian; Writing by Brenda Goh; Editing by Jacqueline Wong)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.03 USD | +1.80% |
|
+5.93% | +4.31% |
12:04am | OPKO Health Raises $250 Million Non-Dillutive Capital Via Note Issue | MT |
Jul. 17 | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
BEIJING (Reuters) - Supplies of Pfizer's Paxlovid in China are still unable to meet demand but local production of the anti-viral COVID drug should be able to start soon, a Chinese health expert said on Wednesday.
Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference.
(Reporting by Yew Lun Tian; Writing by Brenda Goh; Editing by Jacqueline Wong)
1st Jan change | Capi. | |
---|---|---|
+4.31% | 167B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+2.52% | 125B |